XML 17 R2.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2018
Dec. 31, 2017
Current Assets:    
Cash and cash equivalents $ 159,229 $ 187,675
Marketable securities   284,255
Accounts receivable, net of reserves of $4,808 in 2018 and $4,576 in 2017 259,865 234,597
Inventories 179,039 164,318
Other current assets 103,574 101,140
Total current assets 701,707 971,985
Long-Term Assets:    
Property and equipment, net 384,246 379,096
Goodwill 201,022 199,873
Intangible assets, net 41,893 43,846
Other long-term assets 140,624 118,616
Total long-term assets 767,785 741,431
TOTAL ASSETS 1,469,492 1,713,416
Current Liabilities:    
Accounts payable 70,409 66,968
Accrued liabilities 210,384 253,418
Line of credit 407,500 655,000
Current portion of deferred revenue 40,545 29,181
Total current liabilities 728,838 1,004,567
Long-Term Liabilities:    
Deferred income tax liabilities 27,529 25,353
Long-term debt 609,005 606,075
Long-term deferred revenue, net of current portion 68,529 35,545
Other long-term liabilities 84,573 95,718
Total long-term liabilities 789,636 762,691
Total liabilities 1,518,474 1,767,258
Commitments and Contingencies (Note 14)
Stockholders’ Deficit:    
Common stock, $0.10 par value: Authorized: 120,000 shares; Issued: 104,676 shares in 2018 and 104,275 shares in 2017; Outstanding: 86,997 shares in 2018 and 87,104 shares in 2017 10,468 10,428
Additional paid-in capital 1,094,159 1,073,931
Deferred stock units: Outstanding: 217 units in 2018 and 229 units in 2017 5,772 5,988
Retained earnings 880,348 803,545
Accumulated other comprehensive loss (34,206) (36,470)
Treasury stock, at cost: 17,679 shares in 2018 and 17,171 shares in 2017 (2,005,813) (1,911,528)
Total IDEXX Laboratories, Inc. stockholders’ deficit (49,272) (54,106)
Noncontrolling interest 290 264
Total stockholders’ deficit (48,982) (53,842)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT $ 1,469,492 $ 1,713,416